Ignite Creation Date:
2025-12-24 @ 11:48 PM
Ignite Modification Date:
2026-02-18 @ 12:13 PM
Study NCT ID:
NCT01582451
Status:
COMPLETED
Last Update Posted:
2018-04-20
First Post:
2012-04-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
A Comparison of LY2605541 Versus Insulin Glargine Alone or in Combination With Pre-study Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin: An Open-Label, Randomized Study The IMAGINE 5 Study
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMAGINE 5
Brief Summary:
The purpose of this study is to compare LY2605541 and insulin glargine using the following measures after participants have been treated for 26 weeks:
* Change in participants' overall blood sugar control
* The rate of night time low blood sugar episodes
* The number of participants that reach blood sugar targets without low blood sugar episodes at night
* The rate of low blood sugar episodes reported over a 24-hour period
* Change in participants' overall blood sugar control
* The rate of night time low blood sugar episodes
* The number of participants that reach blood sugar targets without low blood sugar episodes at night
* The rate of low blood sugar episodes reported over a 24-hour period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| I2R-MC-BIDJ | OTHER | Eli Lilly and Company | View |